REGENXBIO Inc. (NASDAQ:RGNX) Director Argeris N. Karabelas Sells 10,000 Shares

REGENXBIO Inc. (NASDAQ:RGNX) Director Argeris N. Karabelas sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the transaction, the director now owns 11,286 shares in the company, valued at approximately $114,101.46. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

REGENXBIO Stock Performance

Shares of REGENXBIO stock opened at $9.35 on Friday. The business’s 50 day simple moving average is $12.13 and its 200 day simple moving average is $14.34. REGENXBIO Inc. has a 52-week low of $9.29 and a 52-week high of $28.80. The firm has a market cap of $462.08 million, a PE ratio of -1.59 and a beta of 1.22.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, August 1st. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.24. REGENXBIO had a negative return on equity of 68.21% and a negative net margin of 270.74%. The business had revenue of $22.30 million for the quarter, compared to analyst estimates of $22.97 million. During the same quarter last year, the firm earned ($1.66) EPS. REGENXBIO’s revenue for the quarter was up 11.6% compared to the same quarter last year. As a group, equities research analysts predict that REGENXBIO Inc. will post -4.66 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, September 20th. Barclays reduced their target price on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, August 5th. The Goldman Sachs Group assumed coverage on REGENXBIO in a report on Friday, June 7th. They set a “buy” rating and a $38.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $39.00 target price on shares of REGENXBIO in a report on Wednesday, September 4th. Three investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $37.91.

Institutional Investors Weigh In On REGENXBIO

A number of hedge funds and other institutional investors have recently bought and sold shares of RGNX. Dimensional Fund Advisors LP raised its position in REGENXBIO by 2.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,226,957 shares of the biotechnology company’s stock valued at $22,025,000 after buying an additional 34,385 shares during the last quarter. Perceptive Advisors LLC acquired a new position in shares of REGENXBIO during the 4th quarter worth approximately $6,146,000. Virtu Financial LLC acquired a new position in shares of REGENXBIO during the 4th quarter worth approximately $377,000. PNC Financial Services Group Inc. increased its position in shares of REGENXBIO by 73.5% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,761 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 746 shares during the last quarter. Finally, Napatree Capital LLC acquired a new position in shares of REGENXBIO during the 4th quarter worth approximately $720,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.